Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_1
6
67%
Ph phase_2
3
33%

Phase Distribution

6

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
3(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (66.7%)
Phase 23 (33.3%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

NCT00087165
completedphase_1

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

NCT00459212
completedphase_2

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)

NCT00565058
completedphase_2

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

NCT00068588
completedphase_1

GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT00070551
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00087165Phase 2

GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

Completed
NCT00459212Phase 1

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

Completed
NCT00565058Phase 2

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)

Completed
NCT00068588Phase 2

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

Completed
NCT00070551Phase 1

GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Completed
NCT00084643Phase 1

GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors

Completed
NCT00078962Phase 1

GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed
NCT00074022Phase 1

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

Completed
NCT00056173Phase 1

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9